Who was studied, and how
Five numbers in the abstract
Where each one falls
Where it lands on the map
people with cardiovascular disease, in this paper
The trial randomly assignedassigned by chance
ezetimibe/statin combination therapy
statin monotherapy
Probably lowered plasma concentrations of tumour necrosis factor α−0.48
No clear effect on plasma concentrations of adiponectin+0.34
No clear effect on plasma concentrations of leptin−0.75
randomisedthe abstract, start to end
… of tumour necrosis factor α (TNF-α) (SMD -0.48, 95% CI -0.87, -0.08; P = …
… concentrations of adiponectin (SMD 0.34, 95% CI -0.28, 0.96; P = 0.288), leptin (SMD -0.75, 95% CI: -2.35, 0.85; P = 0.360), plasminogen activator inhibitor 1 (SMD -1.06, 95% CI: -2.81, 0.69; P = 0.236) and interleukin 6 (SMD 0.30, 95% CI: -0.08, 0.67; P = …
← favours treatmentfavours comparator →
could be chancePlasma concentrations of tumour necrosis factor α (TNF-α)ezetimibe/statin combination therapy vs statin monotherapy
−0.48−0.87 to −0.08
Plasma concentrations of adiponectinezetimibe/statin combination therapy vs statin monotherapy
0.34−0.28 to 0.96
Plasma concentrations of leptinezetimibe/statin combination therapy vs statin monotherapy
−0.75−2.35 to 0.85
Plasma concentrations of plasminogen activator inhibitor 1ezetimibe/statin combination therapy vs statin monotherapy
−1.06−2.81 to 0.69
Plasma concentrations of interleukin 6ezetimibe/statin combination therapy vs statin monotherapy
0.30−0.08 to 0.67
StatinsOther lipid agentsPharmacokinetics & dosing
1 / 4